



A Soft-Tissue Preservation and Restoration Company

# INVESTOR PRESENTATION

March 2026

# Forward Looking Statements

This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this document, including but not limited to statements regarding possible or assumed future results of operations, business strategies, development plans, regulatory activities, market opportunity competitive position, potential growth opportunities, and the effects of competition, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause the actual results, performance or achievements of TELA Bio, Inc. (the “Company”) to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this presentation are only predictions. The Company has based these forward-looking statements largely on its current expectations and projections about future events and financial trends that it believes may affect the Company’s business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this presentation and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond the Company’s control, including, among others: the impact to our business from macroeconomic conditions, including recessionary concerns, banking instability, increasing market interest rates, monetary policy changes, changes in trade policies, including tariffs and trade protection measures, and inflationary pressures, potentially impacting our ability to market our products; demand for our products related to changes in volumes or frequency of surgical procedures, including due to outbreak of illness or disease, cybersecurity events impacting hospital operations, potential hospital closures, labor and hospital staffing shortages, supply chain disruptions to critical surgical and hospital supplies, pricing pressures or any other applicable adverse healthcare economic factors; our ability to achieve or sustain profitability; our ability to gain market acceptance for our products and to accurately forecast and meet customer demand; our ability to compete successfully; that data from earlier studies related to our products and interim data from ongoing studies may not be replicated in later studies or indicative of future data; that data obtained from clinical studies using our product may not be indicative of outcomes in other surgical settings; our ability to enhance our product offerings; product development and manufacturing problems; capacity constraints or delays in production of our products; maintenance of coverage and adequate reimbursement for procedures using our products; and product defects or failures. These and other risks and uncertainties are described more fully in the “Risk Factors” section and elsewhere in the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”) and available at [www.sec.gov](http://www.sec.gov). You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in the Company’s forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, the Company operates in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that the Company may face. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.




## Our Mission

We provide innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the **Preservation** and **Restoration** of the patient's own anatomy.

# TELA Bio, Inc.

- ▶ Advanced reinforced tissue matrix portfolio supported by compelling clinical evidence
- ▶ \$2.6B US market opportunity<sup>1</sup> – still in early stages of growth
- ▶ Driving commercial adoption with targeted direct-sales approach
- ▶ Recent product launches in growing markets: robotic hernia surgery, plastic and reconstructive surgery
- ▶ Broad intellectual property portfolio
- ▶ Established DRG-based reimbursement pathway for hernia repair and robust GPO access
- ▶ Highly accomplished executive team with proven track record

1. Management estimate. \$2.6B total includes \$1.8B hernia & abdominal wall reconstruction, \$0.8B plastic reconstructive surgery.




**OVITEXX<sup>®</sup>**  
Reinforced Tissue Matrix

**OVITEXX<sup>®</sup> PRS**  
Reinforced Tissue Matrix

*Redefining soft tissue preservation and restoration with a differentiated category of tissue reinforcement materials and supportive products*

# Product Adoption Since Launch



**~90,000**

OviTex Reinforced Tissue Matrix (RTM) Implantations Globally



**70+**

Published or Presented Works (OviTex + OviTex PRS)



**5,000+**

Hospitals Covered by GPO Access

**~20,000**

OviTex PRS Implantations (U.S.)

**1,500+**

Patients in Peer-Reviewed Publications

# RETHINK REGENERATE RESTORE




Optimized Structure & Biology



Angioconductive ECM



Guided Regeneration




**3**  
**KEY FEATURES**  
that unlock the healing  
and the formation  
of functional,  
remodeled tissue

# OVITEXX<sup>®</sup>

Reinforced Tissue Matrix

# US Hernia Surgery Market

~\$1.8 Billion Annual Opportunity



## Annual Procedures<sup>1</sup>

~105,000

~395,000

~645,000

~42,000

**Robotic / Minimally Invasive Surgery (MIS) Opportunity within the Hernia Market**

*Robotic / MIS compatible procedures total over **1M annually** and have a potential market opportunity of up to **\$1.2B<sup>2</sup>***

1. Sources: Millennium Research Group Reports, IMS Health Data; iData Research MedSKU.  
2. Management estimate. Market size based on volume and weighted average selling price for OviTex.

# One Comprehensive Portfolio



## OviTex Core

4-layer device  
*No smooth sides*

OviTex Core is designed to reinforce primary hernia repairs where the device will not come into contact with viscera .



## OviTex 1S

6-layer device  
*1 smooth side*

OviTex 1S incorporates a smooth side that is designed to minimize tissue attachment and to reinforce primary hernia repairs where the device may come into contact with viscera (e.g. intraperitoneal).



## OviTex 2S

8-layer device  
*2 smooth sides*


OviTex 2S incorporates eight layers of tissue for added strength. The two smooth sides make it suitable for intraperitoneal placement.



## OviTex Low Profile

4-layer device  
*1 smooth side*

OviTex LPR is designed specifically for use in minimally invasive procedures. The design also incorporates a smooth side making it suitable for intraperitoneal placement.



## OviTex Inguinal

4-layer and 3-layer device  
*No smooth sides*

OviTex IHR is designed specifically for use in inguinal hernia repair procedures. The design also incorporates an anatomical and rectangular shape to suit surgeon preference.

# Need for Alternative to Permanent Synthetic Mesh

59%

Of surgeons agree that use of permanent synthetic mesh puts patients at long-term risk of complications<sup>1</sup>

3 of 4

Hernia patients want proactive control in their care<sup>2</sup>

~15,000

Product liability lawsuits relating to permanent synthetic hernia repair (as of November 2024)<sup>3</sup>  
Not inclusive of ~40,000 or more cases settled or dismissed within the past three years<sup>4</sup>

2019

FDA issued multiple 522 orders to manufacturers requiring pre-market approval prior to sale and distribution of transvaginal mesh for pelvic organ prolapse repair<sup>5</sup>

10

Steps surgeons must take in the U.K. as part of the Royal College of Surgeons guidance for Patient Consent Supported Decision Making following the 2015 Montgomery Ruling<sup>6</sup>

1. Hernia and Abdominal Surgeries Survey (Oct 2020). A group of 71 surgeons were surveyed regarding use of mesh in various hernia repair surgeries.

2. Figures derived from Company-sponsored online poll of approximately 1,100 potential patients for hernia procedures.

3. See Medtronic plc Form 10-Q, filed with the SEC on Aug. 27, 2024; Atrium Medical Corp. C-Qur Mesh Products Liability Litigation (Case No: 16-md-2753 LM); In RE: Ethicon Physiomesb Flexible Composite Hernia Mesh Products Liability Litigation (Case No: 1:17-md-02782-RWS).

4. Reuters, "Becton Dickinson agrees to settle about 38,000 hernia mesh suits" (retrieved from <https://www.reuters.com/legal/litigation/becton-dickinson-agrees-settle-about-38000-hernia-mesh-suits-2024-10-03/>); Getinge Press Release, dated December 8, 2021; Johnson & Johnson Form 10-K, filed with the SEC on February 16, 2024 regarding settlement of Ehticon Physiomesb Flexible Composite Mesh claims).

5. U.S. Food and Drug Administration. (n.d.). FDA's activities: Urogynecologic surgical mesh implants. U.S. Department of Health and Human Services. Retrieved from <https://www.fda.gov/news-events/press-announcements/fda-takes-action-protect-womens-health-orders-manufacturers-surgical-mesh-intended-transvaginal>

# 65+ OviTex published or presented works with long term follow-up exceeding 8 years, including:

## VENTRAL / AWR

- ✓ Parker 2021
- ✓ Ankney 2021
- ✓ Sivaraj 2022 (biologic)
- ✓ Sivaraj 2022 (synthetic)
- ✓ DeNoto 2022
- ✓ Goetz 2022
- ✓ Timmer 2022
- ✓ Sweitzer 2024
- ✓ Kim 2025
- ✓ Thomas 2025
- 🔄 BRAVO II (robotic)
- 🔄 Boermeester 5 yr vs. Strattice
- 🔄 Florin (robotic)
- 🔄 Caresyntax: real world data

**803 patients, 1 mo – 5 yr F/U**  
Pending: 1000+ patients

## INGUINAL

- ✓ Ferzoco 2018
- ✓ Ankney 2021
- 🔄 BRAVO II (robotic)
- 🔄 Florin (robotic IHR)
- 🔄 Caresyntax: real world data

**337 patients, 1 mo – 3 yr F/U**  
Pending: 1000+ patients

## HIATAL

- ✓ Sawyer 2018
- 🔄 ECH<sup>2</sup>O<sup>2</sup> (MIS)
- 🔄 Bell, Woodworth (robotic)
- 🔄 Rosen, Krpata RCT
- 🔄 Caresyntax: real world data

**25 patients, 14 mo F/U**  
Pending: 415+ patients

## SPECIALTY / NICHE

- ✓ DeNoto 2022 Bridging
- ✓ Bloemendaal 2023 Parastomal
- ✓ Fernandez 2024 Trauma
- ✓ Lake 2024 Colorectal
- ✓ McCranie 2025 DIEP
- ✓ Landau 2025 Bridging
- ✓ Abed 2025 Renal Transplant
- ✓ Craigie 2025 Pediatrics
- ✓ Baer/ DeLine 2025 Open Abdomen (ACS)
- 🔄 Keller: Parastomal
- 🔄 Broyles: DIEP (IIS)

**186 patients, 1 – 14 mo F/U**  
Pending: 100+ patients

# Favorable Results of OviTex in Ventral Hernia Repair

Comparisons to synthetic mesh and leading first generation biologics

	Parker et al. <sup>3</sup>		Sivaraj et al. <sup>2</sup>			
Total enrolled patients	<b>50 OviTex</b>	50 Polypropylene	<b>36 OviTex</b>	51 Strattice	17 Permacol	37 Surgimend
Length of follow-up	<b>12 months</b>	12 months	<b>28.6 months (median)</b>	34.6 months (median)	58.4 months (median)	37.5 months (median)
mVHWG	<b>32% grade 2 68% grade 3<sup>a</sup></b>	94% grade 2 6% grade 3	<b>33% grade 1 58% grade 2 8% grade 3</b>	17% grade 1 79% grade 2 4% grade 3	18% grade 1 71% grade 2 12% grade 3	40% grade 1 51% grade 2 9% grade 3
CDC wound class	<b>70% CDC class II+<sup>a</sup></b>	94% CDC class I	<b>89% class I-II</b>	86% class I-II	94% class I-II	91% class I-II
Incidence of SSO	<b>36%*</b>	22%*	<b>16.7%*</b>	47.1%*	52.9%*	43.2%*
Incidence of SSI	-	-	<b>2.8%<sup>b</sup></b>	12.5%	11.8%	5.4%
Recurrence rate	<b>6%</b>	12%	<b>2.8%<sup>c</sup></b>	13.7% <sup>c</sup>	29.4%	24.3%

\*Overall complications including surgical site occurrences (SSOs) and surgical site infections (SSIs)

a – OviTex patients were more complicated with a significantly higher mVHWG distribution and CDC wound classification compared to polypropylene patients.

b – OviTex patients experienced significantly less complications than patients receiving the other three biologics.

c – OviTex and Strattice patients had a statistically lower recurrence rate than patients receiving the other two biologics.

Source: Refer to "Clinical References" in this presentation.

# Positive 24-month BRAVO Results In Ventral Hernia

OviTex performance contextualized alongside contemporaneous publications for leading competitive products

	DeNoto et al. (BRAVO) <sup>4</sup>	Harris et al. (PRICE) <sup>11</sup>		Roth et al. <sup>12</sup>	Hope et al. (ATLAS) <sup>13</sup>
<b>Total enrolled patients</b>	92 <b>OviTex</b>	82 Strattice	83 Ventralight ST or Bard Soft Mesh	121 Phasix	120 Phasix ST
<b>Length of follow-up</b>	24 months	26 months		36 months	24 months
<b>mVHWG</b>	78% grade 2-3	-		-	-
<b>CDC wound class</b>	95% class I-II	90% class I-II	93% class I-II	100% class I	100% class I
<b>Surgical technique</b>	Open (65%) Laparoscopic (13%) Robotic (22%)	Open	Open	Open	Laparoscopic (55.8%) Robotic (44.2%)
<b>Incidence of SSO</b>	38% (includes SSI)	21% (excludes SSI)	22% (excludes SSI)	-	0.8% (includes SSI)
<b>Incidence of SSI</b>	20.7%	39%	34%	9%*	0%
<b>Recurrence rate</b>	<b>2.6%*</b>	40% (overall) 34% (class I wounds)	22% (overall) 28% (class I wounds)	17.9%*	31.7%* (overall) 18.6%* (defects < 7cm <sup>2</sup> )


\* Kaplan-Meier survival estimate

\*\*No head-to-head clinical studies have been conducted. Due to differences in patient population, surgeons, surgical technique, and other variables, no direct comparisons of results can be made. For a comparative discussion of these studies, please see G. DeNoto, E.P. Ceppa, S.J. Pacella, M. Sawyer, G. Slayden, M. Takata, G. Tuma, J. Yunis, 24-Month results of the BRAVO study: A prospective, multi-center study evaluating the clinical outcomes of a ventral hernia cohort treated with OviTex® 1S permanent reinforced tissue matrix, Ann Medicine Surg 2022, 83, 104745.

Source: Refer to "Clinical References" in this presentation.

# Hernia Market Evolution

TELA Bio positioned to grow from a market shift towards resorbable and more “natural repair” solutions as an alternative to traditional Permanent Synthetics or Biologics



*Resorbable Synthetics and Reinforced Tissue Matrix strengths:*



Clinical Evidence



Robot Compatibility



Cost-effectiveness



Patient Choice & Shared Decision-making


Sources for Sales Market Share (%): 2009 - 2013 = IMS Hospital Supply Index; 2018 - 2023 = iData Research MedSKU  
 Sources for Total U.S. Market Size: 2021 - 2027 = DRG Hernia Repair Devices Report – 2021; 2013 - 2018 = Management Estimate.  
 Sources for % Robotic Procedures: 2018 - 2027 = DRG Hernia Repair Devices Report – 2021; 2013 = Management Estimate.




**OviTex PRS**  
**Short-Term Resorbable**  
*Available in 2-layer only*

**OviTex PRS**  
**Permanent**  
*Available in 3-layer only*

**OviTex PRS**  
**Long-Term Resorbable**  
*Available in 3-layer only*



**~95% Biologic Building Block**



**Multiple Layers of Ovine Rumen**

**~5% Synthetic Reinforcement**



**Three Polymer Options**

*Blue and red polymer shown for illustrative purposes. The actual polymer is clear.*

**OVITEX<sup>®</sup> PRS**  
Reinforced Tissue Matrix

# US Plastic & Reconstructive Surgery Market

~\$800 Million Annual Opportunity

\$700M<sup>2</sup>

Surgeons use products to reinforce soft tissue during various reconstructive surgeries<sup>1</sup>, including:

- ▶ Head and neck surgery
- ▶ Chest wall reconstruction
- ▶ Pelvic reconstruction
- ▶ Extremities reconstruction
- ▶ Breast reconstruction

Market dominated by human acellular dermal matrices (HADMs):

- ▶ Prone to high degree of stretch
- ▶ Expensive, putting pressure on hospital systems
- ▶ Can experience supply shortages, particularly when large pieces of material are required



Cosmetic Plastic & Reconstructive Surgery


\$100M<sup>2</sup>

1. OviTex PRS is for implantation to reinforce soft tissue where weakness exists in patients requiring soft tissue repair or reinforcement in plastic and reconstructive surgery. The device is supplied sterile and is intended for one-time use. OviTex PRS has not been tested in breast surgical procedures.

2. Management estimate. Source: iData Research MedSKU, Q1 2024. Market size based on sales of current biologics.

# OviTex PRS

Specifically designed for plastic and reconstructive surgery



Available in  
**2-layer resorbable (polyglycolic acid) polymer,**  
**3-layer permanent (polypropylene) polymer,** or **3-layer resorbable (polylactic-co-glycolic acid) polymer** reinforcing the same biologic material

An innovative reinforced tissue matrix designed to improve outcomes by facilitating fluid management and controlling degree and direction of stretch

## Product Features:

- ▶ Layers composed of biologic building block retain biologically significant macromolecules for tissue regeneration<sup>1,2</sup>
- ▶ Diamond embroidery pattern and stents allow for directional flexibility; sawtooth embroidery pattern and slits allow for bi-directional stretch while providing stretch resistance
- ▶ Distinct permeability elements in various configurations – e.g., micropores, macropores, and stents/slits – designed to facilitate fluid management

## OviTex PRS compared to market leading human ADM<sup>3</sup>

- ▶ Exhibited earlier host cell proliferation, collagen deposition and neovascularization
- ▶ Demonstrated tissue remodeling into mature, functional and organized collagen

1. Certain configurations available in two or three layers, see product catalog more information. 2. Lun S, Irvine S.M., Johnson K.D., Fisher N.J., Floden E. W., Negron L., Dempsey S.G., McLaughlin R.J., Vasudevamurthy M., Ward B.R., May B.C., A functional extracellular matrix biomaterial derived from ovine forestomach, *Biomaterials* 31(16) (2010) 4517-29.

3. ADM: Acellular Dermal Matrix. Overbeck N, Beierschmitt A, May BC, Qi S, Koch J. In-Vivo Evaluation of a Reinforced Ovine Biologic for Plastic and Reconstructive Procedures in a Non-human Primate Model of Soft Tissue Repair. *Eplasty*. 2022 Sep 14;22:e43. PMID: 36160663; PMCID: PMC9490877. Animal testing results may not be indicative of clinical performance.



# **LIQUIFIX™**

## **INTERNAL ADHESIVES**

Leading-edge atraumatic hernia mesh fixation devices  
Designed to minimize complications for patient safety and comfort



# LIQUIFIX FIX8™ & LIQUIFIX Precision™



LIQUIFIX FIX8<sup>1</sup> is a complementary product addressing both open and laparoscopic hernia repair in the groin.

## Atraumatic liquid fixation devices

- ▶ Reduce the need for penetrating mechanical fixation for inguinal and femoral hernia repair
- ▶ Provide precise, controlled adhesive application

## Addresses an unmet need in the market, less damage to tissue

- ▶ Designed to minimize the risk of mechanical tissue trauma<sup>2</sup>
- ▶ Strong and secure mesh fixation<sup>2</sup>
- ▶ Pre-assembled device
- ▶ Adhesives polymerize in ~10 seconds
- ▶ Provides versatile liquid anchors at multiple angles

1. LIQUIFIX FIX8 is intended for use in laparoscopic surgical repair of groin (femoral and inguinal) hernias, achieved through the fixation of prosthetic polypropylene or polyester mesh to the abdominal wall and the approximation of the peritoneum; LIQUIFIX Precision is intended for use in open surgical repair of groin (inguinal and femoral) hernias, achieved through the fixation of prosthetic polypropylene or polyester mesh to the abdominal wall.  
2. Data on file: Advanced Medical Solutions

# Driving Revenue Growth



**2021**  
40-45 Reps /  
5 TB Ltd.\*

**2022**  
61 Reps /  
6 TB Ltd.\*

**2023**  
86 Reps /  
9 TB Ltd.\*

**2024**  
63 Territory Managers +  
8 Account Specialists /  
10 TB Ltd.\*

**2025**  
72 Territory Managers +  
20 Account Specialists /  
14 TB Ltd.\*

**2026 (Target)**  
94 Territory Managers +  
17 TB Ltd.\*

- ▶ Playbook90 training (new reps) & ongoing, intensive product training
- ▶ Avg. 6 mos. to breakeven
- ▶ Cadaver labs & other surgeon education & training programs
- ▶ Medical affairs support
- ▶ Industry & society meetings

**OVITEX<sup>®</sup>**  
Reinforced Tissue Matrix

**OVITEX<sup>®</sup> PRS**  
Reinforced Tissue Matrix

**OVITEX<sup>®</sup>**  
Reinforced Tissue Matrix  
INGUINAL

**OVITEX<sup>®</sup>**  
Reinforced Tissue Matrix  
LOW PROFILE

+

**LIQUIFIX FIX8<sup>™</sup>**

**LIQUIFIX Precision<sup>™</sup>**

+


**R&D and BD**

**5,000+**  
**Hospitals**  
covered by  
GPO access

- ▶ BRAVO 24-month data: **2.6%** recurrence
- ▶ **70+** published or presented works for OviTex + OviTex PRS
- ▶ **1,500+** patients in peer-reviewed publications
- ▶ **~90,000** OviTex RTM implantations globally
- ▶ **~20,000** OviTex PRS implantations

\*TB Ltd. = European Sales Force

# Quarterly Revenue and Gross Margin



**Delivering Revenue Growth and Strong Margin with Continuing Improvement Potential**

**66%**

Gross Margin

**\$50.8M**

Cash and Cash  
Equivalents at  
December 31, 2025

**\$21M**

Quarterly revenue of \$20.9M,  
growing 18% over corresponding  
period of 2024